Of those not having undergone RRBSO who had follow‐up in the risk period, 15 of 763 (2% age range = 39.7‐72 years; median = 60.6 years; BRCA1 = 12) died from ovarian cancer post genetic testing. This evidence concerns the gene BRCA1 and ovarian cancer.